Business Description
Arrowhead Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US04280A1007
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.33 | |||||
Equity-to-Asset | 0.16 | |||||
Debt-to-Equity | 2.75 | |||||
Debt-to-EBITDA | -0.91 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -1.59 | |||||
Beneish M-Score | -16.62 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -71.8 | |||||
3-Year EBITDA Growth Rate | -54.2 | |||||
3-Year EPS without NRI Growth Rate | -54.3 | |||||
3-Year Book Growth Rate | -27.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 16.32 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 335.3 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
6-1 Month Momentum % | -22.43 | |||||
12-1 Month Momentum % | -22.43 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.74 | |||||
Quick Ratio | 6.74 | |||||
Cash Ratio | 6.6 | |||||
Days Sales Outstanding | 128.18 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6 | |||||
Shareholder Yield % | -5.47 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -16927.06 | |||||
Net Margin % | -16882.37 | |||||
FCF Margin % | -17779.66 | |||||
ROE % | -209.39 | |||||
ROA % | -68.58 | |||||
ROIC % | -144.96 | |||||
3-Year ROIIC % | -3668.37 | |||||
ROC (Joel Greenblatt) % | -147.29 | |||||
ROCE % | -73.69 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 560.3 | |||||
PB Ratio | 12.4 | |||||
Price-to-Tangible-Book | 13.02 | |||||
EV-to-EBIT | -3.68 | |||||
EV-to-Forward-EBIT | -3.63 | |||||
EV-to-EBITDA | -3.8 | |||||
EV-to-Forward-EBITDA | -14.12 | |||||
EV-to-Revenue | 601.52 | |||||
EV-to-Forward-Revenue | 10.91 | |||||
EV-to-FCF | -3.53 | |||||
Price-to-Median-PS-Value | 15.41 | |||||
Earnings Yield (Greenblatt) % | -27.17 | |||||
FCF Yield % | -26.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Arrowhead Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil MXN) | 61.051 | ||
EPS (TTM) (MXN) | -90.38 | ||
Beta | -0.1 | ||
Volatility % | 18.95 | ||
14-Day RSI | 0 | ||
14-Day ATR (MXN) | 1.620951 | ||
20-Day SMA (MXN) | 454.55 | ||
12-1 Month Momentum % | -22.43 | ||
52-Week Range (MXN) | 454.55 - 586 | ||
Shares Outstanding (Mil) | 124.43 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Arrowhead Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Arrowhead Pharmaceuticals Inc Stock Events
Event | Date | Price(MXN) | ||
---|---|---|---|---|
No Event Data |
Arrowhead Pharmaceuticals Inc Frequently Asked Questions
What is Arrowhead Pharmaceuticals Inc(MEX:ARWR)'s stock price today?
When is next earnings date of Arrowhead Pharmaceuticals Inc(MEX:ARWR)?
Does Arrowhead Pharmaceuticals Inc(MEX:ARWR) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |